Company
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1076 stories · page 4 of 11
Archive
At the close, the UK blue-chip index was up 78.18 points, or 1.1% at 7,423.23, just below the morning peak of 7,441.20 and well above the opening low of 7,345.25
It has received two drug approvals and a priority review
By redirecting the body's natural immune response to target B-cell malignancies, the TNB-486 drug being developed by TeneoTwo could be used alone or in combination, adding a new weapon to AstraZeneca's haematology portfolio
It will file a new drug application later this year
In the longer term, the pharma analysts believe that the drug company “has the potential to build out a platform of antibody-drug conjugates” of which Enhertu is the first
Archive
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news.
Analysts expected a rally in the pharma group's shares following its critical update on breast cancer drug Enhertu at the ASCO conference this weekend
The pharma group still expects full-year revenue percentage growth in the high teens
According to a phase III trial, patients treated with a combination of tremelimumab and Imfinzi experienced a 22% reduction in the risk of death
Deutsche Bank gave the drug-maker a price target of 11,500p, approximately 10% higher than Tuesday’s closing price
AstraZeneca said it believes Enhertu could become the standard of care for a certain group of lung cancer sufferers for whom there is no targeted treatment
Deutsche Bank has raised its price target on stock in the Anglo-Swedish group
Ondexxya was also approved in Japan for use along with all three FXa inhibitors: apixaban, rivaroxaban, or edoxaban
Evusheld may be particularly beneficial for people not adequately protected by a COVID-19 vaccine
“While the results were not what we hoped for, insights from the trial will advance our understanding and application of immunotherapy across our broad clinical development programme, exploring the benefits of Imfinzi in many tumour types,”
Shares in AstraZeneca are at their highest level ever
While vaccines are seen as the first-line defence against COVID-19, the medical regulator said this drug was for those who "may not respond adequately to these vaccines and for a small number of individuals COVID-19 vaccines may not be reco
The litigation with the Chugai Pharmaceutical Company relates to a drug called Ultomiris
The EU drug regulator began reviewing the data on AstraZeneca's antibody cocktail last October
“Hedging macro risk is likely to remain important for equity investors in the near term,” the analysts said
Deal will see AstraZeneca's subsidiary develop, manufacture and commercialise NI006, with initial payment to Neurimmune of US$30mln
The trial results offer the potential to redefine how the disease is classified and treated, the drug giant said
AZ's Saphnelo works by dampening the excessive type I interferon signature that is found in many patients
AZ's Lynparza in combination with a common hormone therapy delayed disease progression versus the current standard of care by more than eight months
Revenues grew 41% with core EPS up 32%; the Anglo-Swedish giant remains bullish on the outlook
Another set of big names reports tomorrow while price rises in the US will set the afternoon tone
Pfizer expects to receive a continued boost from its Covid jab. Investors in AZ and GSK will likely look on in envy
“Bad behaviour from scientists and from politicians has probably killed hundreds of thousands of people"
The company's treatment Imfinzi when used with chemotherapy reduced the risk of death by 20% in patients with advanced biliary tract cancer
The company's treatment Imfinzi when used with chemotherapy reduced the risk of death by 20% in patients with advanced biliary tract cancer
Investments and investor services
In a trial, Enhertu reduced the risk of disease progression or death by 72% versus a prior treatment
Neurimmune will receive an upfront payment of US$30mln from Alexion with potential milestone payments of up to US$730mln
A third dose of the AstraZeneca/Oxford Uni vaccine produced higher levels of neutralising antibodies than those found in persons who had recovered naturally from the alpha, beta and delta variants
If approved, Saphnelo would be the first new treatment for systemic lupus erythematosus (SLE) in Europe in more than a decade
Tezspire is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients, the pharma giant said
Citi recommends Buy of AstraZeneca stock on the back of Evusheld announcement.
If the scientists are to be believed, it looks like being double-jabbed offers less protection against the Omicron variant than the Delta one
The blockbuster acquisition by AstraZeneca distorted the figures somewhat, with the number of M&A deals declining in the quarter
The Anglo-Swedish giant is teaming up with Ionis Pharmaceuticals, which is developing a breakthrough drug for a fatal heart condition
It noted that there is no evidence so far that existing vaccines will not provide protection against the Omicron variant
Archive
The UK blue chip index sank even further while US market fall not as bad as feared
The key question is how governments will respond in the event that the ‘nu’ (B.1.1.529) strain spreads.
"In the UK the vaccine was used to vaccinate older people whereas in Europe people thought initially the vaccine doesn’t work in older people"
Six months of protection was maintained despite the surge of the Delta variant
Both Deutsche Bank and UBS have put out (very short) updates post-results
The company is moving away from the not-for-profit pledge made during the pandemic
Builders and building materials
Trading updates are expected from AstraZeneca, while housebuilders Galliford Try and Redrow have annual general meetings.
Barclays sees AstraZeneca as the top pick in the sector.
Swiss group UBS Tuesday restated its 'buy' advice and £100 a share price target
The candidate demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to standard of care
JPM sees Astra achieving core earnings growth of 33%, 27% and 23% in the next three years
The candidate was found to lead to a stronger immune response and to cause fewer side effects compared to its competitor
"This is the first time a dual immunotherapy regimen has improved overall survival as a 1st-line treatment for patients with unresectable liver cancer for whom treatment options are limited and long-term outcomes are poor," said Susan Galbr
Merck and AstraZeneca have developed medicines that can prevent people infected with the virus from developing serious symptoms
The median price target for AZ shares is £99.91, suggesting upside of 11.5% from current levels. Investment bank Berenberg reckons the stock is worth £105
AZD7442 is the first LAAB with Phase III data to demonstrate benefit in both prophylaxis and treatment of COVID-19, said the pharma giant
Phase III trial results showed showed a 77% reduction in risk of developing symptomatic COVID-19 with the long-acting antibody combination AZD7442
Caleum is investigating a drug to treat light chain amyloidosis, a fatal, rare disease in which abnormal proteins build up in organs throughout the body
While chief executive Pascal Soriot has said he had no regrets over getting involved in vaccines, there is a growing recognition among execs that a rethink may be in order
The pharma giant has racked in successes in its oncology pipeline and it's also entering the rare disease world with Alexion: is it time to move on?
Lynparza used with the current standard of care showed better results than the standard of care alone
Revenue was lifted by the COVID-19 vaccine agreement with AstraZeneca
The new facility is expected to create about 100 highly skilled direct jobs, including scientists and engineers, and further indirect jobs
Two leading banks reckon the the stock could kick on after Monday's move higher
"Immunity is lasting well in the majority of people," Prof Dame Sarah Gilbert told the Telegraph
"It will now be for the (JCVI) to advise on whether booster jabs will be given."
The drug met all primary goals in two late-stage studies involving over 4,000 people
“A third dose for all may be needed, but it may not"
Under the settlement announced by the European Commission, AstraZeneca will deliver 200 million doses by the end of March 2022
Under the settlement announced by the European Commission, AstraZeneca will deliver 200 million doses by the end of March 2022
The anti-cancer vaccine was designed to target two MAGE-type proteins found on many cancer cells
The research team studied records of more than 29mln people who received the first dose of a COVID-19 vaccine between Dec and Apr, and the records of almost 1.8mln people who had been infected with the virus
ALXN1840, a potential new once-daily, oral medicine, demonstrated three times greater copper mobilisation than standard treatments
A phase III trial showed that Forxiga reduced the risk of worsening of renal function, onset of end-stage kidney disease or risk of cardiovascular or renal death by 39%
Reports have suggested the plan is to start vaccinations ahead of the September return to school.
The trial of the group's Ultomiris treatment was halted due to lack of efficacy
The company's AZD7442 drug reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo
“Both of these vaccines, at two doses, are still doing really well against Delta"
“We see Astra’s sector discount unwinding, as the Alexion acquisition demonstrates continued strong top-line growth, coupled with significant operating margin expansion and increased free cash flow generation,” JP Morgan Cazenove said in it
The investment bank resumed coverage with an ‘overweight’ recommendation and a 9,800p target price
The group also announced positive final-stage trial results for Enhertu on breast cancer patients
It’s time we recognised the quality that other countries see in the UK, and back ourselves by investing more money"
Trial patients experienced a reduction in organ damage and needed fewer oral corticosteroids, which can cause side effects
"Is the vaccine business a sustainable business for AstraZeneca for the next five or 10 years/"
In the first half of the year, the COVID-19 vaccine delivered sales twice the consensus view
The group said the efficacy and safety of Ultomiris in children and teens are consistent with what has been demonstrated in adults.
The approval was based on positive results from a phase III trial where Imfinzi showed improvement compared to chemotherapy alone
Before the committee’s meeting, the FDA issued a briefing document that said the drug’s safety in CKD patients was the main issue
Rare diseases "represent a high-growth opportunity with rapid innovation and significant unmet medical needs", the company said
Archive
Arkle Resources* (AIM:ARK) – Drilling at Tombreen encounters gold in the first four holes of the current campaign Atalaya Mining (AIM:ATYM) – Mineral reserves and resources update for Cerro Colorado and San Dionisio Petra Diamonds (LON:PDL)
A final decision is expected in the first quarter of 2022
UBS has prepared a list of European stocks ahead of results season where it expects the numbers to exceed expectations
The pharma giant is still waiting for the green light from the UK
Here we provide an intro to antibody-drug conjugates, the latest weapon in the fight against cancer
Public Health England said the jab is 92% effective against hospitalisation from the strain
It is the first time a drug for neurofibromatosis type 1 has been approved in the region
The pharma giant said a judge at the Court of First Instance in Brussels had ruled it had to supply 80.2mln doses by September 27, lower than the 120mln deamdned by the European Commission
Two doses of a COVID-19 vaccine helped reduce the risk
The candidate is also being studied as prevention in individuals not already infected, with results yet to be published
The group also posted positive results from a late-stage trial on its breast cancer candidate Lynparza
